Compare RCEL & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | SEER |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 111.4M |
| IPO Year | N/A | 2020 |
| Metric | RCEL | SEER |
|---|---|---|
| Price | $4.30 | $1.79 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.88 | N/A |
| AVG Volume (30 Days) | 216.1K | ★ 399.6K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | $21.69 | $2.14 |
| Revenue Next Year | $49.58 | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $3.22 | $1.62 |
| 52 Week High | $10.28 | $2.41 |
| Indicator | RCEL | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 44.11 |
| Support Level | $4.11 | $1.71 |
| Resistance Level | $4.57 | $1.97 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 5.52 | 26.14 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.